 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | 177Lu HTK03170 / BC Cancer Agency
Trial initiation date, Metastases: 177Lu-HTK03170 in mCRPC With PSMA Positive Disease (clinicaltrials.gov) - Aug 1, 2023
P1/2, N=50, Not yet recruiting, Sponsor: British Columbia Cancer Agency
Initiation date: Mar 2023 --> Oct 2023
- | 177Lu HTK03170 / BC Cancer Agency
Trial completion date, Trial initiation date, Trial primary completion date, Metastases: 177Lu-HTK03170 in mCRPC With PSMA Positive Disease (clinicaltrials.gov) - Dec 1, 2022
P1/2, N=50, Not yet recruiting, Sponsor: British Columbia Cancer Agency
Initiation date: Mar 2023 --> Oct 2023 Trial completion date: Dec 2027 --> May 2027 | Initiation date: Dec 2022 --> Mar 2023 | Trial primary completion date: Dec 2026 --> Mar 2026
- | 177Lu HTK03170 / BC Cancer Agency
New P1/2 trial, Metastases: 177Lu-HTK03170 in mCRPC With PSMA Positive Disease (clinicaltrials.gov) - Oct 7, 2022
P1/2, N=56, Not yet recruiting, Sponsor: British Columbia Cancer Agency